Aimt stock zacks
Aimmune Therapeutics, Inc. (AIMT) Stock Price, Quote ... Find the latest Aimmune Therapeutics, Inc. (AIMT) stock quote, history, news and other vital information to help you with your stock trading and investing. Aimmune Therapeutics: 4Q Earnings Snapshot The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.05 per share. For the year, the company reported that its loss widened to $248.5 million, or $3.97 per share. Aimmune Therapeutics shares have dropped 27% since the beginning of the year. AIMT News Today (Aimmune Therapeutics) | MarketBeat What's going on at Aimmune Therapeutics (NASDAQ:AIMT)? View breaking news headlines for AIMT stock from trusted media outlets at MarketBeat. Zacks Investment Research Upgrades Aimmune Therapeutics ...
Aimmune Therap stocks price quote with latest real-time prices, charts, financials Aimmune Therap (AIMT) Jim Giaquinto - ZACKS - Sat Apr 4, 12:15AM CDT.
What Makes Aimmune Therapeutics (AIMT) a New Buy Stock. 06-13 zacks.com Aimmune Therapeutics (AIMT - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. AIMT AIMT Stock Quote - Aimmune Therapeutics, Inc. Common Stock ... Stock quote for Aimmune Therapeutics, Inc. Common Stock Common Stock (AIMT) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Is the Options Market Predicting a Spike in Aimmune (AIMT ... Feb 21, 2020 · Investors in Aimmune Therapeutics, Inc. AIMT need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 20, 2020 $30 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows AIMT:NASDAQ GS Stock Quote - Aimmune Therapeutics Inc ...
AIMT - Aimmune Therapeutics Inc Stock quote - CNNMoney.com
AIMT News Today (Aimmune Therapeutics) | MarketBeat What's going on at Aimmune Therapeutics (NASDAQ:AIMT)? View breaking news headlines for AIMT stock from trusted media outlets at MarketBeat. Zacks Investment Research Upgrades Aimmune Therapeutics ...
Feb 19, 2020 Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call Zacks Equity Research February 19, 2020.
AIMT Stock Price, Forecast & News (Aimmune Therapeutics) Analyzing Aimmune Therapeutics (NASDAQ:AIMT) stock? View AIMT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. AIMT Aimmune Therapeutics, Inc. Stock Quote What Makes Aimmune Therapeutics (AIMT) a New Buy Stock Zacks Jun-12-19 08:00AM Aimmune to Present at the JMP Securities Life Sciences Conference Business Wire AIMT Stock Price | Aimmune Therapeutics Inc. Stock Quote ... AIMT | Complete Aimmune Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Is the Options Market Predicting a Spike in Aimmune (AIMT ...
Aimmune Therapeutics, Inc. (AIMT) Stock Price, Quote ...
The Zacks Personal Finance Channel provides guidance about investing, insurance, retirement planning and taxes so readers can make informed decisions about their financial futures.
One stock that I find interesting and will be tracking carefully is my Stock of the Week, Aimmune Therapeutics , which I posted this morning. AIMT has developed a 'desensitivity' treatment for AIMT Aimmune Therapeutics — Stock Price and Discussion ... Apr 03, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Is the Options Market Predicting a Spike in Aimmune (AIMT ... Currently, Aimmune is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 33% of our Zacks Industry Rank. Over the last 30 days, the Zacks Consensus Estimate for the current quarter has moved from a loss of $1.04 per share to a loss of $1.05 per share . (AIMT) : Free Stock Analysis Report To read AIMT (Aimmune Therapeutics) Stock Price and Chart - StockAP